Event
Connect with Quotient Sciences at the upcoming 14th Drug Delivery and Formulation Summit in Berlin from 31st May to 2nd June.
Schedule a meeting
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Services
At Quotient Sciences, we have streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Latest updates
-
NewsQuotient Sciences Supports Crinetics Pharmaceuticals with Fully Integrated Pediatric Development and Clinical Testing ProgramCrinetics Pharmaceuticals and Quotient Sciences announce a partnership to support Crinetics’ CRN04894 pediatric program.
-
Jun 5Tradeshow & ConferenceBIO International Convention 2023 | Boston, MAQuotient Sciences will be at the BIO International Convention 2023 in Boston, June 5-8. Schedule a meeting with us to discuss our integrated drug development services. Also, be sure to join our lunch seminar on Tuesday, 6th June from 11:30am at The Westin Seaport. Get details now!
-
WhitepaperSynthesis to Clinic: A streamlined approach to 14C human ADME studiesWe are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.
-
Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD TrialQuotient Sciences has supported Evecxia with the Phase 1 two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram. Favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data was announced from the study.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.